SYNC.L acquires FRLN for $6.50/ADS—a 51% premium to the “unaffected” share price on 10/17/23: https://www.globenewswire.com/news-release/2023/11/22/2784727/0/en/Syncona-to-Acquire-Freeline-Therapeutics.html The nominal deal value is $28M. The buyout price of $6.50 is a 64% discount to FRLN’s IPO in 2020 (#msg-157451134).